Akebia Therapeutics has scrapped plans for trial that would have potentially led to an expansion of the patient population for its new anemia drug Vafseo, the company said.

Akebia shares decline after the company ends plans for its VALOR trial, citing FDA feedback and high costs tied to expanding ...

The proposed trial aimed to study the use of vadadustat to treat anemia in patients with late-stage chronic kidney disease not on dialysis. The treatment is already approved for such patients who have ...

New professional guidance to the nation's pediatricians advises against using a drug in children with autism that many families are clamoring for after it was hyped by federal officials.

Shares of Akebia Therapeutics fell sharply premarket after it abandoned plans for a clinical trial of its anemia treatment in patients not on kidney dialysis following a meeting with the Food and Drug ...

The Aplastic Anemia market presents opportunities in novel therapies, with 5+ companies and 8+ drugs in various development stages. Key focus is on innovative treatment approaches, partnerships, and ...

Metro Atlanta hospitals won't discuss policies around newborn drug testing, despite consequences for families reported.

The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...

Studies show patients with chronic kidney disease (CKD) and COVID-19 are at increased risk for an intensive care unit stay and early death. Anemia is an extra risk factor.

The most common cholesterol drug around might help protect cancer patients from "chemo brain." Statins appeared to protect ...

In the U.S., Vafseo® (vadadustat) is approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for at least three months. Nephrologists in the U.S. began prescribing ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.